Phase 1 dose escalation for VIP943 – first antibody-drug conjugate (ADC) from VersAptx™, versatile and adaptable, next-generation bioconjugation platform – moves quickly into 2nd cohort
Phase 1 dose escalation for VIP236 – first-in-class small molecule-drug conjugate (SMDC) for treatment of solid tumors – progressing well with optimized dosing schedule
Phase 1 dose escalation combination study for enitociclib in collaboration with NIH – partial response in first patient dosed in second cohort
Cash balance expected to support planned operations into late 2024
PALO ALTO, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
“This has been a standout quarter for Vincerx, with progress across all three clinical programs, including VIP943, our first ADC from the VersAptx Platform, our versatile and adaptable, next-generation bioconjugation platform, and VIP236, our first-in-class SMDC,” said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx. “The Vincerx team has done an outstanding job delivering ahead of expectations. Not only were we able to dose our first VIP943 patient within a matter of weeks of FDA clearance, but we have quickly moved through our first cohort and are beginning enrollment in our second cohort. This momentum is a testament to the promising safety profile seen in the first cohort and the enthusiasm from investigators participating in the trial. We expect to report preliminary data from this study in mid-2024.”
“We also continued to make excellent progress with our other clinical programs. VIP236, our first-in-class SMDC for advanced solid tumors, is dosing patients under an optimized dosing schedule of once every three weeks, and we are pleased with the early safety profile we are seeing. We expect to report preliminary data in early 2024. In addition, enitociclib, our CDK9 inhibitor, continues to show promise. The transformed follicular lymphoma patient in our monotherapy study remains on treatment and has achieved long-term stable disease for more than 16 months with a 51% reduction in target lesions. Furthermore, our collaboration with the National Institute of Health (NIH) on a Phase 1 dose-escalation study of enitociclib with venetoclax and prednisone continues to make progress, with four patients dosed and an overall favorable safety profile. Even more exciting, the first patient on the second dose level remains on study with a partial response with evidence of an 80% reduction in the pulmonary lesion and resolution of skin lesions from their peripheral T-cell lymphoma,” added Dr. Hamdy.
“We continue to take a very disciplined approach to our portfolio, focusing our resources on our two lead programs, VIP943 and VIP236. Concurrently, we are exploring business development opportunities that can advance all of our clinical programs as well as leverage the power of our VersAptx Platform. The therapeutic and safety potential of ADCs and other conjugates is being widely recognized, as evidenced by the overall excitement and activity in the ADC space, including collaborations, acquisitions, and positive clinical results. We believe that our next-generation ADC technology represents a significant step forward in the treatment of cancer by potentially overcoming the safety and efficacy challenges associated with many ADCs. As a result, we feel we are well-positioned to capitalize on industry enthusiasm for bioconjugates,” concluded Dr. Hamdy.
Third Quarter 2023 Corporate Highlights:
VIP943: CD123-KSPi ADC for leukemias and myelodysplastic syndrome
VIP236: SMDC with αvβ3 integrin binder linked to optimized CPT payload for solid tumors
VIP924: CXCR5-KSPi ADC for B-cell malignancies
Enitociclib: CDK9 inhibitor for hematologic malignancies and solid tumors
Additional Corporate Highlights
Third Quarter 2023 Financial Results
About Vincerx Pharma, Inc.
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company committed to developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. Vincerx has assembled a seasoned management team with a proven track record of successful oncology drug development, approvals, and value creation. Vincerx’s diverse pipeline consists of the next-generation antibody-drug conjugate, VIP943, in Phase 1; small molecule-drug conjugate, VIP236, in Phase 1; preclinical antibody-drug conjugate, VIP924; CDK9 inhibitor, enitociclib, currently in an NIH-sponsored Phase 1; and VersAptx, its versatile and adaptable, next-generation bioconjugation platform.
Vincerx is based in Palo Alto, California, and has a research facility in Monheim, Germany. For more information, please visit www.vincerx.com.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “suggest,” “seek,” “intend,” “plan,” “goal,” “potential,” “on-target,” “on track,” “project,” “estimate,” “anticipate,” or other comparable terms. All statements other than statements of historical facts included in this press release are forward-looking statements. Forward-looking statements include, but are not limited to: Vincerx’s business model, expected cash runway, pipeline, strategy, timeline, product candidates and attributes, and preclinical and clinical development, timing, and results. Forward-looking statements are neither historical facts nor assurances of future performance or events. Instead, they are based only on current beliefs, expectations, and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of Vincerx’s control.
Actual results, conditions, and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results, conditions, and events to differ materially from those indicated in the forward-looking statements include, but are not limited to: general economic, financial, legal, political, and business conditions; risks associated with preclinical or clinical development and trials, including those conducted prior to Vincerx’s in-licensing; failure to realize the benefits of Vincerx’s license agreement with Bayer; risks related to the rollout of Vincerx’s business and the timing of expected business and product development milestones; changes in the assumptions underlying Vincerx’s expectations regarding its future business or business model; Vincerx’s ability to successfully develop and commercialize product candidates; Vincerx’s capital requirements and availability and uses of capital; and the risks and uncertainties set forth in Form 10-Q for the quarter ended June 30, 2023 and other reports filed with the Securities and Exchange Commission by Vincerx. Forward-looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements.
Vincerx, the Vincerx logo, CellTrapper, and VersAptx are our trademarks. This press release also contains trademarks and trade names that are the property of their respective owners.
Contacts
Joyce Lonergan
LifeSci Advisors, LLC
781-528-5276
jlonergan@lifesciadvisors.com
Vincerx Pharma, Inc. Condensed Consolidated Balance Sheets (in thousands) |
|||||||
September 30, 2023 | December 31, 2022 | ||||||
(unaudited) | |||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 15,078 | $ | 11,663 | |||
Short-term marketable securities | 5,724 | 40,796 | |||||
Prepaid expenses | 322 | 134 | |||||
Other current assets | 1,694 | 3,371 | |||||
Total current assets | 22,818 | 55,964 | |||||
Right-of-use assets | 2,447 | 3,064 | |||||
Property, plant and equipment, net | 137 | 177 | |||||
Other assets | 874 | 81 | |||||
Total assets | $ | 26,276 | $ | 59,286 | |||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
Current liabilities | |||||||
Accounts payable | $ | 3,062 | $ | 4,065 | |||
Accrued expenses | 4,526 | 3,923 | |||||
Lease liability | 1,126 | 1,024 | |||||
Common stock warrant liabilities | 132 | 144 | |||||
Total current liabilities | 8,846 | 9,156 | |||||
Lease liability, net of current portion | 1,639 | 2,412 | |||||
Other noncurrent liabilities | 50 | 50 | |||||
Total liabilities | 10,535 | 11,618 | |||||
Total stockholders’ equity | 15,741 | 47,668 | |||||
Total liabilities and stockholders’ equity | $ | 26,276 | $ | 59,286 | |||
Vincerx Pharma, Inc. Condensed Consolidated Statements of Operations (unaudited) (in thousands, except per share amounts) |
||||||||||||||||
For the three months ended | For the nine months ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Operating expenses: | ||||||||||||||||
General and administrative | $ | 3,517 | $ | 4,525 | $ | 11,816 | $ | 14,903 | ||||||||
Research and development | 6,800 | 11,066 | 25,260 | 40,779 | ||||||||||||
Restructuring | – | 1,310 | – | 2,469 | ||||||||||||
Total operating expenses | 10,317 | 16,901 | 37,076 | 58,151 | ||||||||||||
Loss from operations | (10,317 | ) | (16,901 | ) | (37,076 | ) | (58,151 | ) | ||||||||
Other income (expense) | ||||||||||||||||
Change in fair value of warrant liabilities | 112 | (79 | ) | 12 | 6,334 | |||||||||||
Interest income | 260 | 204 | 1,053 | 204 | ||||||||||||
Other income (expense) | 230 | (103 | ) | 804 | (111 | ) | ||||||||||
Total other income (expense) | 602 | 22 | 1,869 | 6,427 | ||||||||||||
Net loss | $ | (9,715 | ) | $ | (16,879 | ) | $ | (35,207 | ) | $ | (51,724 | ) | ||||
Net loss per common share, basic and diluted | $ | (0.46 | ) | $ | (0.80 | ) | $ | (1.66 | ) | $ | (2.46 | ) | ||||
Weighted average common shares outstanding, basic and diluted | 21,345 | 21,083 | 21,269 | 20,992 | ||||||||||||
FORT WORTH, Texas, Dec. 24, 2024 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) today announced…
- Proprietary data and samples from TRACERx and Achilles’ Material Acquisition Platform (MAP) will be…
If you are male and in your 40's and 50's and feel your testosterone levels…
Transforming Anxiety into Positive Energy: A New Approach by The Anxiety ClinicBondi Junction, New South…
Embracing Mental Well-Being During the Festive SeasonCarlton North, Australia--(Newsfile Corp. - December 24, 2024) -…
If you are researching the strongest over the counter weight loss supplements in 2025 -…